Sangeeta Mahajan, MD
Urogynecology and Reconstructive Pelvic Surgery · Mayfield Hts, OHNPI 1568488807
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,015 of the $47,508 with a category attached, or 65.3%. 28 manufacturers reported payments, led by AbbVie at 55.6% of the total. Reporting peaked in 2019 at $15,843 and has fallen 89.6% since, to $1,647 in 2025. Among urogynecology and reconstructive pelvic surgery clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 342 payments — averaging $138.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$26K
- Astellas Pharma US Inc$14K
- Axonics, Inc.$2K
- Boston Scientific$1K
- Medtronic$1K
- Pfizer$590
- plus $2K from 22 others
Across 38 payments — averaging $2375.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ironwood Pharmaceuticals, Inc$49K
- AbbVie$41K
What the payments were for
- Consulting fees$2,2755%
- Speaking & faculty fees$31,01565%
- Travel & lodging$4,51910%
- Food & beverage$9,36820%
- Education$800%
- Gifts$2511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 126 | $26,405 |
| Astellas Pharma US Inc | 63 | $13,792 |
| Axonics, Inc. | 27 | $1,898 |
| Boston Scientific | 20 | $1,209 |
| Medtronic(2 entities) | 15 | $1,122 |
| Pfizer | 28 | $590 |
| Caldera Medical, Inc | 11 | $525 |
| Teleflex LLC | 3 | $458 |
| Sumitomo Pharma America, Inc. | 20 | $417 |
| Coloplast | 3 | $196 |
| Davol Inc. | 1 | $158 |
| Coopersurgical, Inc. | 3 | $125 |
| Intuitive Surgical | 1 | $101 |
| Amgen | 3 | $78 |
| Urovant Sciences Inc | 4 | $67 |
| Aspira Women's Health Inc | 1 | $66 |
| Johnson & Johnson | 1 | $43 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $38 |
| Hologic Sales And Service, LLC | 2 | $36 |
| Bayer | 1 | $31 |
| Laborie Medical Technologies Corp. | 1 | $29 |
| Merz Pharmaceuticals, LLC | 1 | $23 |
| Bluewind Medical | 1 | $23 |
| Applied Medical Technology Inc | 1 | $20 |
| Convatec Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $14 |
| Dentsply IH Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$24,175
- MYRBETRIQ$12,557
- Axonics r-SNM System$1,315
- Bulkamid$1,240
- INTERSTIM$365
- Barrigel$350
- ADVANTAGE FIT$248
- ARISTA AH FLEXITIP$158
- BOTOX COSMETIC$114
- Desara$113
- Axonics$111
- SOLYX$108
- Advantage System$108
- Da Vinci Surgical System$101
How this compares
$47,508 in reported general payments places this provider in the 95th percentile of 60 urogynecology and reconstructive pelvic surgery providers in Ohio.
See all urogynecology and reconstructive pelvic surgery providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 105 | $80,991 |
| GemtesaVibegron | 52 | $34,952 |
| Estradiol | 331 | $24,023 |
| PremarinEstrogens, Conjugated | 21 | $10,328 |
| Trospium Chloride | 165 | $10,297 |
| Mirabegron ErMirabegron | 12 | $9,562 |
| Trospium Chloride ErTrospium Chloride | 28 | $7,658 |
| EstringEstradiol | 12 | $6,311 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 295 | $5,241 |
| Methenamine Hippurate | 36 | $4,596 |
| YuvafemEstradiol | 26 | $4,419 |
| Solifenacin Succinate | 110 | $4,021 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 29 | $2,680 |
| Tolterodine Tartrate ErTolterodine Tartrate | 22 | $1,926 |
| Trimethoprim | 29 | $1,806 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $13,792 | $80,991105 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $417 | $34,95252 claims |
| PfizerPremarin, Estring | $590 | $16,63933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 60 urogynecology and reconstructive pelvic surgery providers in Ohio.
Other urogynecology and reconstructive pelvic surgery in Mayfield Hts
- Costas ApostolisStrongsville$982K
- Mickey KarramWest Chester$127K
- Emily SlopnickCleveland$37K
- Mitesh ParekhZanesville$33K
- Andrew CroakMaumee$26K
- Ly Hoang RobertsCleveland$23K
- Marie ParaisoCleveland$20K
- Omer AnisCleveland$17K
- Nadine KassisToledo$15K
- Chen ShenharCleveland$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.